Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2017

View Archived Issues

OBI Pharma acquires TH-3424 from Threshold Pharmaceuticals

Universita degli Studi di Sassari patents amniotic cells with phagocytic activity

Etelcalcetide receives U.S. orphan designation for pediatric hyperparathyroidism

Baltaleucel-T cell therapy given FDA orphan status for post-transplant lymphoproliferative disorder

ReNeuron reports FDA feedback for CTX stroke disability program

U.S. orphan designation given to recombinant fibroblast growth factor receptor 3 for achondroplasia

PeptiDream, Shionogi and Sekisui Chemical form new company

UMB grants rights to vaccine technology to Serenta Biotechnology

Crestone presents promising phase I data for CRS-3123

Adocia begins two studies of BioChaperone products for diabetes

Sevion Therapeutics to acquire Eloxx Pharmaceuticals

First patient enrolled in DELIVERS trial of Castle Creek Pharmaceuticals' CCP-020

Merck KGaA collaborates with F-star on bispecific immuno-oncology antibodies

Pain Therapeutics awarded NIH grant to advance Alzheimer's disease drug candidate

Researchers develop a novel assay to quantify inducible, replication competent latent HIV-1

First-in-human results reported for novel antifungal VL-2397

KGF does not improve clinical outcome in patients with acute respiratory distress syndrome

Debiopharm reports first-in-human data for FGFR inhibitor Debio-347

Novo Nordisk grants exclusive rights to IPH-5401 to Innate Pharma

MaxCyte enters CRADA with NIAID on X-linked chronic granulomatous disease

Amgen submits applications in E.U. and U.S. for CV outcomes data for Repatha

ACEA and Memorial Sloan Kettering collaborate on personalized CAR T-cell therapy

Cel-Sci responds to FDA regarding clinical hold on phase III study of Multikine

Novartis and Bristol-Myers Squibb collaborate to evaluate Mekinist with Opdivo in colorectal cancer

AntriaBio submits IND application for AB-101

Velo Bio enrolls first patient in phase IIb/IIIa study of digoxin immune Fab

First clinical data presented for the anti-TNFRSF18 agonist BMS-986156 in solid tumors

Cornerstone Pharmaceuticals announces name change

Survival data reported for CMB-305 in NY-ESO-1+ recurrent soft tissue sarcomas

BMS and Seattle Genetics to test nivolumab/brentuximab vedotin combination